Characterization of TAP Ambr 250 disposable bioreactors, as a reliable scale‐down model for biologics process development

Demands for development of biological therapies is rapidly increasing, as is the drive to reduce time to patient. In order to speed up development, the disposable Automated Microscale Bioreactor (Ambr 250) system is increasingly gaining interest due to its advantages, including highly automated control, high throughput capacity, and short turnaround time. Traditional early stage upstream process development conducted in 2 ‐ 5 L bench‐top bioreactors requires high foot‐print, and running cost. The establishment of the Ambr 250 as a scale‐down model leads to many benefits in process development. In this study, a comprehensive characterization of mass transfer coefficient (kLa) in the Ambr 250 was conducted to define optimal operational conditions. Scale‐down approaches, including dimensionless volumetric flow rate (vvm), power per unit volume (P/V) and kLa have been evaluated using different cell lines. This study demonstrates that the Ambr 250 generated comparable profiles of cell growth and protein production, as seen at 5‐L and 1000‐L bioreactor scales, when using kLa as a scale‐down parameter. In addition to mimicking processes at large scales, the suitability of the Ambr 250 as a tool for clone selection, which is traditionally conducted in bench‐top bioreactors, was investigated. Data show that cell growth, productivity, metabolite profiles, and product qualities of material generated using the Ambr 250 were comparable to those from 5‐L bioreactors. Therefore, Ambr 250 can be used for clone selection and process development as a replacement for traditional bench‐top bioreactors minimizing resource utilization during the early stages of development in the biopharmaceutical industry. © 2017 American Institute of Chemical Engineers Biotechnol. Prog., 33:478–489, 2017

[1]  Andrew Tait,et al.  Automated disposable small-scale bioreactor for high-throughput process development: implementation of the 24 bioreactor array , 2015 .

[2]  Rashmi Kshirsagar,et al.  Application of high‐throughput mini‐bioreactor system for systematic scale‐down modeling, process characterization, and control strategy development , 2015, Biotechnology progress.

[3]  J. H. Rushton,et al.  Power Characteristics of Mixing Impellers part 1 , 1950 .

[4]  S. Nagata,et al.  Power Characteristics of Mixing Impellers , 1956 .

[5]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[6]  Zizhuo Xing,et al.  Scale‐up analysis for a CHO cell culture process in large‐scale bioreactors , 2009, Biotechnology and bioengineering.

[7]  Christian Bailly,et al.  Strategies and challenges for the next generation of therapeutic antibodies , 2010, Nature Reviews Immunology.

[8]  Christopher Miller,et al.  High‐throughput miniaturized bioreactors for cell culture process development: Reproducibility, scalability, and control , 2014, Biotechnology progress.

[9]  Thomas Ryll,et al.  Development of a scale down cell culture model using multivariate analysis as a qualification tool , 2014, Biotechnology progress.

[10]  D. King,et al.  High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.

[11]  P. Sharp,et al.  Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary dna gene. , 1982, Journal of molecular biology.

[12]  K. Riet,et al.  Review of Measuring Methods and Results in Nonviscous Gas-Liquid Mass Transfer in Stirred Vessels , 1979 .

[13]  Thomas Ryll,et al.  Application of bioreactor design principles and multivariate analysis for development of cell culture scale down models , 2015, Biotechnology and bioengineering.

[14]  Rachel Bareither,et al.  Automated disposable small scale reactor for high throughput bioprocess development: A proof of concept study , 2013, Biotechnology and bioengineering.

[15]  F Baganz,et al.  Quantification of power consumption and oxygen transfer characteristics of a stirred miniature bioreactor for predictive fermentation scale‐up , 2008, Biotechnology and bioengineering.

[16]  Feng Li,et al.  A Systematic Approach for Scale‐Down Model Development and Characterization of Commercial Cell Culture Processes , 2006, Biotechnology progress.

[17]  W. Hsu,et al.  Advanced microscale bioreactor system: a representative scale-down model for bench-top bioreactors , 2012, Cytotechnology.

[18]  C. Hewitt,et al.  Agitation conditions for the culture and detachment of hMSCs from microcarriers in multiple bioreactor platforms , 2016 .

[19]  Mitchell Tai,et al.  Efficient high‐throughput biological process characterization: Definitive screening design with the Ambr250 bioreactor system , 2015, Biotechnology progress.

[20]  Chris D. Rielly,et al.  The physical characterisation of a microscale parallel bioreactor platform with an industrial CHO cell line expressing an IgG4 , 2013 .